TNFAIP2 and acute myeloid leukemia: TNFAIP2 expression level was significantly lower in AML patients with favorable cytogenetic risk compared with those with intermediate (Supplementary Fig. S3b, P < 0.001) or unfavorable cytogenetics risk (Supplementary Fig. S3b, P < 0.001).